skip navigation

Skip Nav

Clinical Guidelines Portal

skip navigation

Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Appendix C: Panel Roster and Financial Disclosures

CMV

(Last updated:11/1/2012; last reviewed:11/1/2012)

Cytomegalovirus Disease
Member Financial Disclosure
Company Relationship
Boeckh, Michael*
University of Washington School of Medicine Astellas Consultant
Chimerix Consultant, Research Support 
Clinigen Consultant
Genentech/Roche
Consultant, Research Support 
Gilead Consultant
Glaxo-Smith-Kline
Consultant
Merck Consultant, Research Support 
Vical Consultant
ViroPharma Consultant, Research Support 
Chimerix Advisory Board, Honoraria, Speaker’s Bureau
Griffiths, Paul

 
 
 
 
 
 
 
 
University College London, England

 
 
 
 
 
 
 
 
Astellas Advisory Board, Honoraria
Boehringer-Ingelheim
Advisory Board, Honoraria
GlaxoSmithKline
Advisory Board
Merck Advisory Board
Microbiotix
Advisory Board, Honoraria
Novartis Speaker's Bureau
Sanofi-Pasteur Other
Vical Advisory Board
ViroPharma
Advisory Board, Honoraria, Speaker’s Bureau
Jabs, Douglas
Mt. Sinai School of Medicine
Abbott Consultant
Alcon Consultant
Allergen Consultant
Applied Genetic Technologies Corporation
Consultant
Corcept Therapeutics
Consultant
Genetech Consultant
Genzyme Consultant
GlaxoSmithKline
Consultant
Novartis Consultant
Regeneron Consultant
Jacobson, Mark
University of California San Francisco
Up To Date Other
Cellex Research Support
Kimberlin, David
University of Alabama at Birmingham
Cubist Research Support
GlaxoSmithKline
Research Support
Abbott Research Support
Weinberg, Adriana

 
 
 
 
University of Colorado

 
 
 
 
Astellas Research Support
Becton-Dickenson
Research Support
MedImmune Research Support
Medtronic Research Support
Merck Research Support
*Group lead

Note: Members were asked to disclose all relationships from 24 months before the writing panel convened. The period of reporting was from June 1, 2008, through November 1, 2012.